NCT04828057View on ClinicalTrials.gov

Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

August 24, 2022

Study Completion Date

August 24, 2022

Conditions

Ocular Surface DiseasePrimary Open Angle Glaucoma

Interventions

DRUG

Tafluprost, timolol maleate

Patients prescribe PG mono who occurs OSD or I IOP lower insufficient. patients switch to combination therapy.

Trial Locations (1)

333012

Chang-Geng Medical Foundation Linkou Chang-Geng Memorial Hospital, Taoyuan

All Listed Sponsors

lead

Santen Pharmaceutical (Taiwan) Co., LTD

INDUSTRY

NCT04828057 - Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting | Biotech Hunter | Biotech Hunter